BRPI0606740A2 - compostos de bis arila e heteroarila substituìdas como antagonistas de 5ht2a seletivos - Google Patents

compostos de bis arila e heteroarila substituìdas como antagonistas de 5ht2a seletivos

Info

Publication number
BRPI0606740A2
BRPI0606740A2 BRPI0606740-9A BRPI0606740A BRPI0606740A2 BR PI0606740 A2 BRPI0606740 A2 BR PI0606740A2 BR PI0606740 A BRPI0606740 A BR PI0606740A BR PI0606740 A2 BRPI0606740 A2 BR PI0606740A2
Authority
BR
Brazil
Prior art keywords
heteroaryl compounds
selective
compounds substituted
antagonists
bis aryl
Prior art date
Application number
BRPI0606740-9A
Other languages
English (en)
Inventor
David Mark Fink
Helen Katherine Smith
Richard Simon Todd
Hazel Hunt
Paul Robert Eastwood
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of BRPI0606740A2 publication Critical patent/BRPI0606740A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18Benzotriazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSTOS DE BIS ARILA E HETEROARILA SUBSTITUìDAS COMO ANTAGONISTAS DE 5HT2 2A2 SELETIVOS. A presente invenção refere-se a uma série de compostos de bis arila e heteroarila substituidas da fórmula (1): em que X, Y, Z, A, 6, D, Ar, R2 12 e R2 22 são como definidos aqui. Os compostos desta invenção são antagonistas de 5HT2 2A2 seletivos, e são portanto, úteis no tratamento de uma variedade de doenças incluindo porém não limitado a uma ampla variedade de distúrbios do sono como descrito e reivindicado aqui.
BRPI0606740-9A 2005-02-10 2006-02-10 compostos de bis arila e heteroarila substituìdas como antagonistas de 5ht2a seletivos BRPI0606740A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65191105P 2005-02-10 2005-02-10
PCT/US2006/004879 WO2006086705A1 (en) 2005-02-10 2006-02-10 Substituted bis aryl and heteroaryl compounds as selective 5ht2a antagonists

Publications (1)

Publication Number Publication Date
BRPI0606740A2 true BRPI0606740A2 (pt) 2009-07-14

Family

ID=36577530

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606740-9A BRPI0606740A2 (pt) 2005-02-10 2006-02-10 compostos de bis arila e heteroarila substituìdas como antagonistas de 5ht2a seletivos

Country Status (23)

Country Link
US (1) US7625889B2 (pt)
EP (1) EP1851199B1 (pt)
JP (1) JP5419355B2 (pt)
KR (1) KR20070107037A (pt)
CN (1) CN101115717A (pt)
AR (1) AR052903A1 (pt)
AU (1) AU2006213634A1 (pt)
BR (1) BRPI0606740A2 (pt)
CA (1) CA2598429A1 (pt)
CR (1) CR9260A (pt)
DO (1) DOP2006000032A (pt)
GT (1) GT200600042A (pt)
IL (1) IL185173A0 (pt)
MA (1) MA29289B1 (pt)
MX (1) MX2007008606A (pt)
NO (1) NO20074583L (pt)
PA (1) PA8662501A1 (pt)
PE (1) PE20061088A1 (pt)
RU (1) RU2007133655A (pt)
TN (1) TNSN07272A1 (pt)
TW (1) TW200640859A (pt)
UY (1) UY29372A1 (pt)
WO (1) WO2006086705A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754238B2 (en) 2003-07-22 2014-06-17 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
PE20061130A1 (es) 2004-11-19 2007-01-05 Arena Pharm Inc Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a
BRPI0614943A2 (pt) * 2005-08-19 2011-04-26 Aventis Pharma Inc combinação de um agente hipnótico e composto de bisarila e heteroarila substituìdo e aplicação terapêutica da mesma
US8927546B2 (en) * 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
US7829713B2 (en) * 2006-02-28 2010-11-09 Helicon Therapeutics, Inc. Therapeutic piperazines
EP2001870A2 (en) 2006-03-31 2008-12-17 Schering Corporation Kinase inhibitors
US8148418B2 (en) 2006-05-18 2012-04-03 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
USRE45336E1 (en) 2006-05-18 2015-01-13 Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
NZ594353A (en) 2006-05-18 2013-02-22 Arena Pharm Inc Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物
JP5393677B2 (ja) * 2007-08-15 2014-01-22 アリーナ ファーマシューティカルズ, インコーポレイテッド 5−HT2Aセロトニン受容体に関連した障害の治療のための5−HT2Aセロトニン受容体のモジュレーターとしてのイミダゾ[1,2−a]ピリジン誘導体
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010045190A1 (en) 2008-10-15 2010-04-22 Boehringer Ingelheim International Gmbh Fused heteroaryl diamide compounds useful as mmp-13 inhibitors
JP5529876B2 (ja) 2008-10-17 2014-06-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Mmp−13阻害剤として有用なヘテロアリール置換インドール化合物
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
HRP20180589T1 (hr) 2008-10-28 2018-05-18 Arena Pharmaceuticals, Inc. Pripravci modulatora serotoninskog receptora 5-ht2a koji su korisni za liječenje s njim povezanih poremećaja
US8980891B2 (en) 2009-12-18 2015-03-17 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US9139576B2 (en) 2011-05-03 2015-09-22 Merck Sharp & Dohme Corp. Aminomethyl biaryl benzotriazole derivatives
WO2014077762A1 (en) 2012-11-13 2014-05-22 Ge Healthcare Bio-Sciences Ab Multimodal anion exchange matrices
CA2986083A1 (en) 2015-06-11 2016-12-15 Basilea Pharmaceutica International AG Efflux-pump inhibitors and therapeutic uses thereof
RU2017145976A (ru) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
TW201720439A (zh) 2015-07-15 2017-06-16 Axovant Sciences Gmbh 用於預防及治療與神經退化性疾病相關的幻覺之作為5-ht2a血清素受體的二芳基及芳基雜芳基脲衍生物
CN106854189A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种哌嗪化合物的合成方法
CN107778257A (zh) * 2016-08-29 2018-03-09 湖南华腾制药有限公司 一种哌嗪衍生物的合成方法
CN106977463A (zh) * 2017-05-31 2017-07-25 湖南华腾制药有限公司 一种联苯取代哌嗪衍生物的合成方法
RS67273B1 (sr) 2017-08-21 2025-10-31 Acadia Pharm Inc Jedinjenja, njihove soli i njihova upotreba u lečenju bolesti
EP3672960A2 (en) * 2017-08-21 2020-07-01 Acadia Pharmaceuticals Inc. Compounds, salts thereof and their use for the treatment of diseases
US12293809B2 (en) 2019-08-23 2025-05-06 Insilico Medicine Ip Limited Workflow for generating compounds with biological activity against a specific biological target
WO2021038419A1 (en) * 2019-08-23 2021-03-04 Insilico Medicine Ip Limited Kinase inhibitors and methods of synthesis and treatment
WO2022249113A1 (ko) * 2021-05-25 2022-12-01 주식회사 자이메디 Aimp2-dx2와 kras의 결합을 억제하는 신규 화합물 및 이의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8305245D0 (en) * 1983-02-25 1983-03-30 Fujisawa Pharmaceutical Co Imidazo-heterocyclic compounds
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
CN1206996C (zh) * 1998-06-09 2005-06-22 武田药品工业株式会社 用于治疗或预防睡眠障碍的药物组合物
JP2004507439A (ja) * 1999-07-16 2004-03-11 ブリストル−マイヤーズ スクイブ ファーマ カンパニー Xa因子阻害剤としての窒素含有ヘテロ二環式化合物
DE19934433A1 (de) * 1999-07-22 2001-01-25 Merck Patent Gmbh N-(Indolcarbonyl-)piperazinderivate
US6573049B1 (en) * 1999-07-26 2003-06-03 Nuvelo, Inc. Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
AU2002223968A1 (en) * 2000-12-21 2002-07-01 Warner Lambert Company Llc Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists
DE10209520A1 (de) * 2002-03-04 2003-09-25 4Sc Ag Neue Modulatoren von Kaliumkanälen
US7342115B2 (en) * 2002-11-08 2008-03-11 Neurogen Corporation 3-substituted-6-aryl pyridines
GEP20084341B (en) * 2003-02-26 2008-03-25 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors
EP2295433A3 (en) * 2003-03-06 2011-07-06 Eisai R&D Management Co., Ltd. JNK inhibitors
US7700638B2 (en) * 2003-10-23 2010-04-20 N. V. Organon 1,5,7-trisubstituted benzimidazole derivatives and their use for modulating the GABAA receptor complex
JP4777974B2 (ja) * 2004-04-01 2011-09-21 イーライ リリー アンド カンパニー ヒスタミンh3受容体作用物質、製剤および治療的使用
US20060014733A1 (en) * 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
KR20070046150A (ko) * 2004-07-28 2007-05-02 아이알엠 엘엘씨 스테로이드 호르몬 핵 수용체의 조절제로서의 화합물 및조성물

Also Published As

Publication number Publication date
JP5419355B2 (ja) 2014-02-19
JP2008530120A (ja) 2008-08-07
CN101115717A (zh) 2008-01-30
IL185173A0 (en) 2007-12-03
PE20061088A1 (es) 2006-11-29
CA2598429A1 (en) 2006-08-17
MA29289B1 (fr) 2008-02-01
GT200600042A (es) 2006-09-27
NO20074583L (no) 2007-10-12
US7625889B2 (en) 2009-12-01
KR20070107037A (ko) 2007-11-06
MX2007008606A (es) 2007-09-11
PA8662501A1 (es) 2006-09-08
EP1851199B1 (en) 2012-05-16
TW200640859A (en) 2006-12-01
UY29372A1 (es) 2006-10-02
TNSN07272A1 (en) 2008-12-31
CR9260A (es) 2007-10-04
WO2006086705B1 (en) 2006-11-16
AU2006213634A1 (en) 2006-08-17
WO2006086705A1 (en) 2006-08-17
AR052903A1 (es) 2007-04-11
DOP2006000032A (es) 2006-08-15
RU2007133655A (ru) 2009-03-20
EP1851199A1 (en) 2007-11-07
US20070265309A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
BRPI0606740A2 (pt) compostos de bis arila e heteroarila substituìdas como antagonistas de 5ht2a seletivos
CY1109568T1 (el) Ενωσεις βενζο(d)ισοξαζολ-3-υλαμινης και η χρησιμοποιηση τους σαν προσδεματα υποδοχεα βανιλλοειδων
CY1112495T1 (el) Κυτταροτοξικοι παραγοντες που περιλαμβανουν νεα παραγωγα τομαϋμυκινης
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
EA201070423A1 (ru) Диарильные соединения оксадиазолов
UA87153C2 (ru) Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы
ATE407938T1 (de) Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
NO20065178L (no) Tienopyridinderivater
NO20072608L (no) Biaryloksymetylarenkarboksylsyrer
DE602004007693D1 (de) (3-oxo-3,4-dihydro-chinoxalin-2-yl-amino)-benzamid-derivate und verwandte verbindungen als glykogen-phosphorylase-hemmer zur behandlung von diabetes und adipositas
ES2335410T8 (es) Derivados de aminopropanol.
EA200600323A1 (ru) γd-КРИСТАЛЛИЧЕСКАЯ ФОРМА ГИДРОХЛОРИДА ИВАБРАДИНА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ ЕЁ СОДЕРЖАТ
TW200630374A (en) Thiazolyldihydroindazoles
CY1111327T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
NO20080394L (no) N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav
ATE347555T1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
TW200738692A (en) New substituted glycinamides, process for their manufacture and use thereof as medicaments
ATE446753T1 (de) Verwendung von substituierten 2-thio-3,5-dicyano- 4-phenyl-6-aminopyridinen bei der behandlung von übelkeit und erbrechen
DE602007008691D1 (de) Cyclische sulfone, die zur verwendung als bace-inhibitoren geeignet sind
TW200612964A (en) Methods for preparing p2x7 inhibitors
NO20072060L (no) 2-acylaminotiazolderivater
TW200722424A (en) Substituted piperidines
TW200702330A (en) 3,4,5-Substituted piperidines
CY1107101T1 (el) Μεθοδος συνθεσης παραγωγων της 1,3-διϋδρο-2h-3-βενζαζεπιν-2-ονης και εφαρμογη στη συνθεση της ιβαβραδινης και των αλατων προσθηκης με φαρμακευτικως αποδεκτο οξυ

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: AVENTIS PHARMACEUTICALS, INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070165509/RJ DE 23/11/2007.

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]